本文来源:时代财经 作者:李傲华图片来源:图虫创意“过去两天,估计整个医药投资界都在讨论和学习统计学。康方生物这是以一己之力带动了业界统计学知识的交流和水平的提升。”一名不愿具名的行业人士对时代财经开玩笑称。4月26日凌晨,康方生物(09926.HK)公布称,其自主研发的全球首创PD-1/VEGF双特异性抗体新药依达方(通用名:依沃西单抗注射液)的新适应症获得了国家药监局(NMPA)的批准上市。...
Source Link本文来源:时代财经 作者:李傲华图片来源:图虫创意“过去两天,估计整个医药投资界都在讨论和学习统计学。康方生物这是以一己之力带动了业界统计学知识的交流和水平的提升。”一名不愿具名的行业人士对时代财经开玩笑称。4月26日凌晨,康方生物(09926.HK)公布称,其自主研发的全球首创PD-1/VEGF双特异性抗体新药依达方(通用名:依沃西单抗注射液)的新适应症获得了国家药监局(NMPA)的批准上市。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.